Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neuroblastoma 9Prostatic Neoplasms 3Precancerous Conditions 3Glioma 3Astrocytoma 3Adenomatous Polyposis Coli 3Skin Neoplasms 2Sarcoma, Ewing 2Osteosarcoma 2Neuroectodermal Tumors, Primitive 2Medulloblastoma 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Basal Cell 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Typical Teratoid Rhabdoid Tumor 1Stomach Neoplasms 1Rhabdoid Tumor 1Osteosarcoma Recurrent 1Oligodendroglioma 1Non-melanoma Skin Cancer 1Neoplasms 1Melanoma 1Lymphoma, Follicular 1Lung Neoplasms 1Keratosis, Actinic 1Gastritis, Atrophic 1Esophageal Neoplasms 1

Interventions

Fluorouracil 497Bevacizumab 476Oxaliplatin 449Leucovorin 440Irinotecan 408Cetuximab 317Capecitabine 317pembrolizumab 142Folfox protocol 129Panitumumab 117regorafenib 105Colonoscopy 88Nivolumab 81IFL protocol 81Drug Therapy 77trifluridine tipiracil drug combination 73Radiotherapy 66HMPL-013 65Blood Specimen Collection 52Gemcitabine 49Specimen Handling 46Neoadjuvant Therapy 45Standard of Care 44Magnetic Resonance Spectroscopy 43Biopsy 43Chemotherapy, Adjuvant 41Trifluridine 40atezolizumab 38Surveys and Questionnaires 38Cyclophosphamide 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Eflornithine × Clear all
NCT01349881 2026-04-02

PACES

SWOG Cancer Research Network

Phase 3 Active not recruiting
354 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT00033371 2020-09-29

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Completed
205 enrolled 16 charts
Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡